Cancer Drug Trials Need More Older Volunteers, FDA Says

March 5, 2020, 4:03 PM

Drugmakers would develop better cancer treatments for elderly populations if they included more of them in their clinical trials, the FDA said Thursday in policy recommendations to improve representation for older patients.

“Older adults are underrepresented in cancer clinical trials despite representing a growing segment of the population of cancer patients,” according to the recommendations. Research shows roughly 60% of cancers occur in those 65 years of age or older. Still, that group doesn’t participate in clinical trials at an equitable rate.

The push to add more people 65 years or older to clinical trials is part of the ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.